ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.226,82
-0,22%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,1354
0,12%
Bitcoin
65.871,78
7,03%
Brent Oil
82,71
0,19%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) Notícias

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ESPR
DataHoraFonteTítuloCódigoCompanhia
14/05/202409:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
10/05/202417:00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
08/05/202417:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202409:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
07/05/202407:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202409:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202409:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
07/04/202415:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202409:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202409:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
25/03/202417:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
22/03/202419:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202416:10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202412:04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
27/02/202411:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
27/02/202408:00GlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
14/02/202416:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
13/02/202410:00GlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
01/02/202416:00GlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
23/01/202418:00GlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
22/01/202408:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
18/01/202423:15GlobeNewswire Inc.Esperion Announces Pricing of $85.1 Million Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
18/01/202418:00GlobeNewswire Inc.Esperion Announces Proposed Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
03/01/202417:15Business WireEsperion e Daiichi Sankyo Europe annunciano un emendamento da 125 milioni di dollari alla loro collaborazione, compresa la risoluzione di una controversia in corsoNASDAQ:ESPREsperion Therapeutics Inc
03/01/202415:54Business WireEsperion et Daiichi Sankyo Europe annoncent une révision de leur collaboration pour un montant s’élevant à 125 millions USD, assortie de la résolution d’un litige en coursNASDAQ:ESPREsperion Therapeutics Inc
03/01/202412:07Business WireEsperion und Daiichi Sankyo Europe geben Anpassung ihrer Zusammenarbeit in Höhe von 125 Millionen US-Dollar sowie die Beilegung eines anhängigen Rechtsstreits bekanntNASDAQ:ESPREsperion Therapeutics Inc
03/01/202409:00Business WireEsperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationNASDAQ:ESPREsperion Therapeutics Inc
18/12/202310:00GlobeNewswire Inc.Esperion to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
13/12/202318:46Dow Jones NewsEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA ApprovalNASDAQ:ESPREsperion Therapeutics Inc
13/12/202318:00GlobeNewswire Inc.U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) TabletNASDAQ:ESPREsperion Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ESPR

Seu Histórico Recente

NASDAQ
PLAB
Photronics
KUCN
SHRBTC
ShareToken
CSE
DIGI
DigiMax Global
COIN
BBNCUSD
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados